Biggest changeResults of Operations The following table sets forth certain statement of operations items from continuing and discontinued operations and as a percentage of revenue, for the periods indicated (in $000’s): Fiscal Year Ended December 28, 2024 Fiscal Year Ended December 30, 2023 Statement of Operations Data: Revenue $ 12,532 $ — Cost of revenue 6,238 — Gross profit 6,294 — Selling, general and administrative expenses 13,856 4,746 Impairment charges — 15,100 Operating loss (7,562) (19,846) Interest (expense) income, net (879) 2,250 Gain on litigation settlement 374 — Unrealized loss on marketable securities (1,058) (926) Other income, net (161) 998 Net loss before provision for income taxes (9,286) (17,524) Income tax benefit (3,041) (429) Net loss income from continuing operations (6,245) (17,095) Income from discontinued operations — 10,254 Income tax provision for discontinued operations — 971 Net income from discontinued operations — 9,283 Net loss $ (6,245) $ (7,812) 69 Table of Contents The following tables set forth revenues for key product and service categories, percentages of total revenue and gross profits earned by key product and service categories and gross profit percent as compared to revenues for each key product category indicated (in $000’s): Fiscal Year Ended December 28, 2024 Fiscal Year Ended December 30, 2023 Net Revenue Percent of Total Net Revenue Percent of Total Revenue Fintech $ 12,532 100 % $ — — % Biotech — — % — — % Corporate and other — — % — — % Discontinued operations — — % 3,795 100 % Total revenue $ 12,532 100 % $ 3,795 100 % Fiscal Year Ended December 28, 2024 Fiscal Year Ended December 30, 2023 Gross Profit Gross Profit % Gross Profit Gross Profit % Gross Profit Fintech $ 6,294 50 % $ — — % Biotech — — % — — % Corporate and other — — % — — % Discontinued operations — — % (197) (5) % Total gross profit $ 6,294 50 % $ (197) (5) % Revenue Revenue increased by approximately $8.8 million for the fiscal year ended December 28, 2024, as compared to the year ended December 30, 2023.
Biggest changeAdjusted EBITDA (Non-GAAP) Fintech Biotech (Discontinued Operations) Total Reportable Segments Corporate and Other Total Income (loss) before income taxes $ (8,310 ) $ (3,898 ) $ (12,208 ) $ (419,918 ) $ (432,126 ) Interest expense, net 2,754 — 2,754 1,114 3,868 Depreciation and amortization 3,339 1,929 5,268 — 5,268 Stock based compensation — — — 5,901 5,901 Unrealized loss on cryptocurrency assets — — — 402,054 402,054 Other adjustments (394 ) — (394 ) — (394 ) Adjusted EBITDA $ (2,611 ) $ (1,969 ) $ (4,580 ) $ (10,849 ) $ (15,429 ) Results of Operations The following table sets forth certain statement of operations items from continuing and discontinued operations and as a percentage of revenue, for the periods indicated (in $000’s): Fiscal Year Ended December 27, 2025 Fiscal Year Ended December 28, 2024 Statement of Operations Data: Revenue $ 24,840 $ 11,887 Cost of revenue 14,652 6,238 Gross profit 10,188 5,649 Selling, general and administrative expenses 33,039 12,572 Impairment charges — — Operating loss (22,851 ) (6,923 ) Interest expense, net (3,869 ) (1,159 ) Realized (loss) gain on exchange transactions 374 1,019 Unrealized loss on marketable securities — (1,238 ) Unrealized loss on cryptocurrency assets (402,054 ) — Unrealized gain on exchange transactions 768 — Other expense, net (596 ) (160 ) Net loss before provision for income taxes (428,228 ) (8,461 ) Income tax expense (benefit) (86,742 ) (160 ) Net loss income from continuing operations (341,486 ) (8,301 ) Loss from discontinued operations (3,898 ) (2,148 ) Income tax benefit from discontinued operations (877 ) (2,881 ) Net (loss) income from discontinued operations (3,021 ) 733 Net loss $ (344,507 ) $ (7,568 ) 28 Table of Contents The following tables set forth revenues for key product and service categories, percentages of total revenue and gross profits earned by key product and service categories and gross profit percent as compared to revenues for each key product category indicated (in $000’s): Fiscal Year Ended December 27, 2025 Fiscal Year Ended December 28, 2024 Net Revenue Percent of Total Net Revenue Percent of Total Revenue Fintech $ 24,840 100 % $ 11,887 100 % Biotech — — % — — % Corporate and other — — % — — % Total revenue $ 24,840 100 % $ 11,887 100 % Fiscal Year Ended December 27, 2025 Fiscal Year Ended December 28, 2024 Gross Profit Gross Profit % Gross Profit Gross Profit % Gross Profit Fintech $ 10,188 41 % $ 5,649 48 % Biotech — — % — — % Corporate and other — — % — — % Total gross profit $ 10,188 41 % $ 5,649 48 % Revenue Revenue increased by approximately $13.0 million for the fiscal year ended December 27, 2025, as compared to the year ended December 28, 2024.
The short-term intended result of that series of 71 Table of Contents transactions would be for us to own a controlling interest in that subsidiary, but to decouple it from us so that it would operate on a stand-alone basis, although its financial statements would continue to be consolidated with ours for as long as we have a controlling interest.
The short-term intended result of that series of transactions would be for us to own a controlling interest in that subsidiary, but to decouple it from us so that it would operate on a stand-alone basis, although its financial statements would continue to be consolidated with ours for as long as we have a controlling interest.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For a description of our significant accounting policies and an understanding of the significant factors that influenced our performance during the fiscal year ended December 28, 2024, this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (hereafter referred to as “MD&A”) should be read in conjunction with the consolidated financial statements, including the related notes, appearing in Part II, Item 8 of this 10-K for the fiscal year ended December 28, 2024.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For a description of our significant accounting policies and an understanding of the significant factors that influenced our performance during the fiscal year ended December 27, 2025, this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (hereafter referred to as “MD&A”) should be read in conjunction with the consolidated financial statements, including the related notes, appearing in Part II, Item 8 of this 10-K for the fiscal year ended December 27, 2025.
We intend to raise funds to support future development of JAN 123 either through capital raises or structured arrangements, which would include effectuating our previously announced intention to capitalize a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary.
We intend to raise funds to support future development of JAN123 either through capital raises or structured arrangements, which would include effectuating our previously announced intention to capitalize a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary.
Management regularly reviews its estimates and assumptions, which are 68 Table of Contents based on historical factors and other factors believed to be relevant under the circumstances. Actual results may differ from these estimates under different assumptions, estimates or conditions.
Management regularly reviews its estimates and assumptions, which are based on historical factors and other factors believed to be relevant under the circumstances. Actual results may differ from these estimates under different assumptions, estimates or conditions.
We operate three reportable segments: • Fintech: Our Fintech segment provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets • Biotechnology: Our Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.
During the periods disclosed in this Annual Report, we operated three segments: Fintech Our Fintech segment provides next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets. 26 Table of Contents Biotechnology Our Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.
Our 2024 fiscal year ended on December 28, 2024 (“fiscal 2024”). Our 2023 fiscal year ended on December 30, 2023 (“fiscal 2023”). Application of Critical Accounting Policies Our discussion of the financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in conformity with accounting principles generally accepted in the United States.
Application of Critical Accounting Policies Our discussion of the financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in conformity with accounting principles generally accepted in the United States.
Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties and potentially result in materially different results under different assumptions and conditions. Critical accounting policies include intangible impairment under ASC 350, revenue recognition under ASC 606, and going concern under ASC 205.
Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties and potentially result in materially different results under different assumptions and conditions.
We reported a net loss of approximately $6.2 million for the fiscal year ended December 28, 2024, and net loss from continuing operations of approximately $17.1 million for the fiscal year ended December 30, 2023, for the reasons discussed above.
We reported a net loss from continuing operations of approximately $341.5 million for the fiscal year ended December 27, 2025, and net loss from continuing operations of approximately $8.3 million for the fiscal year ended December 28, 2024, for the reasons discussed above.
Interest Income (Expense), net Interest expense, net, was approximately $880,000 for the fiscal year ended December 28, 2024, as compared to interest income, net, of approximately $2.3 million for the year ended December 30, 2023.
Interest Expense, net Interest expense, net, was approximately $3.9 million for the fiscal year ended December 27, 2025, as compared to approximately $1.2 million for the year ended December 28, 2024.
The increase is due to the acquisition of ALT5 Subsidiary during May 2024, partially offset by no revenue from discontinued operations for the fiscal year ended December 28, 2024. Gross Profit Gross profit increased by approximately $6.5 million for the fiscal year ended December 28, 2024, as compared to the year ended December 30, 2023.
The increase is due to the acquisition of ALT5 Subsidiary during May 2024, as well as the acquisition of Mswipe during May 2025. Gross Profit Gross profit increased by approximately $4.6 million for the fiscal year ended December 27, 2025, as compared to the year ended December 28, 2024.
Additionally, the Company has total current assets of approximately $35.0 million and total current liabilities approximately of $40.9 million, resulting in a net negative working capital of approximately $5.9 million. Cash provided operations was approximately $1.0 million. In Item 1A.
Additionally, the Company has total current assets of approximately $29.5 million and total current liabilities approximately of $51.4 million, resulting in a net negative working capital of approximately $21.9 million. Cash used in operations was approximately $7.2 million.
Future Sources of Cash; New Acquisitions, Products and Services We acquired ALT5 Subsidiary during May 2024, as discussed above. We may require additional debt financing and/or capital to finance new acquisitions or consummate other strategic investments in our business.
Future Sources of Cash; New Acquisitions, Products and Services We may require additional debt financing and/or capital to finance new acquisitions, conduct our Phase IIb clinical trials for our Biotechnology segment, or consummate other strategic investments in our business.
We currently expect that the biotechnology subsidiary transaction discussed above will allow us to finance our Phase IIb clinical trials, No assurance can be given any financing obtained may not further dilute or otherwise impair the ownership interest of our existing stockholders or our ownership interest in the to-be-effectuated biotechnology subsidiary. 72 Table of Contents Off Balance Sheet Arrangements At December 28, 2024, we had no off-balance sheet arrangements, commitments or guarantees that require additional disclosure or measurement.
No assurance can be given any financing obtained may not further dilute or otherwise impair the ownership interest of our existing stockholders. Off Balance Sheet Arrangements At December 27, 2025, we had no off-balance sheet arrangements, commitments or guarantees that require additional disclosure or measurement.
Cash provided by investing activities was approximately $5.9 million for the fiscal year ended December 28, 2024, compared to cash used in investing activities of approximately $156,000 for the fiscal year ended December 30, 2023.
There was no cash used in operating activities for discontinued operations during the fiscal years ended December 27, 2025 or December 28, 2024. Cash used in investing activities was approximately $706.6 million for the fiscal year ended December 27, 2025, compared to cash provided by investing activities of approximately $5.9 million for the fiscal year ended December 28, 2024.
We have previously announced our intention to capitalize a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary.
We have previously announced our intention to capitalize a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in the financing of that subsidiary. The short-term intended result of that series of transactions would be to decouple it from us so that it would operate on a stand-alone basis.
Selling, General and Administrative Expense Selling, general and administrative expenses from continuing operations increased by approximately $7.6 million for the fiscal year ended December 28, 2024, as compared to the year ended December 30, 2023, primarily due to the acquisition of ALT5 Subsidiary during May 2024, increased amortization costs relating to the Soin intangibles in our Biotech segment, and increased stock-based compensation expense related to grants of RSU's, as well as costs for professional services in our Corporate and Other segment.
Selling, General and Administrative Expense Selling, general and administrative expenses from continuing operations increased by approximately $20.5 million for the fiscal year ended December 27, 2025, as compared to the year ended December 28, 2024, primarily due to the acquisitions of ALT5 Subsidiary in May 2024 and Mswipe in May 2025, as well as higher bad debt and legal expenses and increased stock-based compensation from RSU grants.
Results of Operations by Segment The following table sets forth the results of operations by segment (in $000’s): Fiscal Year Ended December 28, 2024 Fiscal Year Ended December 30, 2023 Fintech Biotech Corporate and other Discontinued Operations Total Fintech Biotech Corporate and other Discontinued Operations Total Revenue $ 12,532 $ — $ — $ — $ 12,532 $ — $ — $ — $ 3,795 $ 3,795 Cost of revenue 6,238 — — — 6,238 — — — 3,992 3,992 Gross profit 6,294 — — — 6,294 — — — (197) (197) Selling, general and administrative expense 5,389 2,148 6,206 — 13,743 — 1,531 3,215 1,467 6,213 Impairment charges — — — — — — — 15,100 — 15,100 Gain on sale of ARCA — — — — — — — — (12,102) (12,102) Operating (loss) income 905 (2,148) (6,206) — (7,449) — (1,531) (18,315) 10,438 (9,408) Fintech Segment Our Fintech segment consists of ALT5 Subsidiary, which was acquired during May 2024.
Results of Operations by Segment The following table sets forth the results of operations by segment (in $000’s): Fiscal Year Ended December 27, 2025 Fiscal Year Ended December 28, 2024 Fintech Biotech (Discontinued Operations) Corporate and other Total Fintech Biotech (Discontinued Operations) Corporate and other Total Revenue $ 24,840 $ — $ — $ 24,840 $ 11,887 $ — $ — $ 11,887 Cost of revenue 14,652 — — 14,652 6,238 — — 6,238 Gross profit 10,188 — — 10,188 5,649 — — 5,649 Selling, general and administrative expense 16,370 3,898 16,669 36,937 5,456 2,148 7,116 14,720 Impairment charges — — — — — — — — Gain on sale of ARCA — — — — — — — — Operating (loss) income (6,182 ) (3,898 ) (16,669 ) (26,749 ) 193 (2,148 ) (7,116 ) (9,071 ) Fintech Segment Our Fintech segment consists of ALT5 Subsidiary, which was acquired during May 2024, as well as Mswipe, which was acquired during May 2025.
Cash provided by investing activities for the fiscal year ended December 28, 2024 was related to cash acquired in the acquisition of ALT5 Subsidiary, while cash used in investing activities for the fiscal year ended December 30, 2023 was all associated with discontinued operations and was related to purchases of property and equipment.
Cash used in investing activities for the fiscal year ended December 27, 2025 was primarily the purchase of WLFI tokens, partially offset by tokens redeemed during the period, while cash provided by investing activities for the fiscal year ended December 28, 2024 was related to cash acquired in the acquisition of ALT5 Subsidiary.
Revenue for the fiscal year ended December 28, 2024 was approximately $12.5 million, and gross margin percentage was 50.2%. Operating income for the fiscal year ended December 28, 2024 was approximately $900,000. Biotech Segment Our Biotech segment generated no revenue for the fiscal year ended December 28, 2024.
Revenue for the fiscal year ended December 27, 2025 was approximately $24.8 million, and gross margin percentage was 41.0%. Operating loss for the fiscal year ended December 27, 2025 was approximately $6.2 million. Corporate and Other Segment Our Corporate and Other segment generated no revenue for the fiscal year ended December 27, 2025.
We had no discontinued operations during the fiscal year ended December 28, 2024. The change in cash was primarily due to results of operations as discussed above.
Cash Flows During the fiscal year ended December 27, 2025, cash used in operations was approximately $7.2 million, compared to cash provided by operations of approximately $1.8 million during the fiscal year ended December 28, 2024. The decrease in cash was primarily due to results of operations as discussed above.
Sources of Liquidity We acknowledge that we continue to face a challenging competitive environment as we continue to focus on our overall profitability, including managing expenses.
There was no cash used in financing activities for discontinued operations during the fiscal years ended December 27, 2025 or December 28, 2024 Sources of Liquidity We acknowledge that we continue to face a challenging competitive environment as we continue to focus on our overall profitability, including managing expenses.
Unrealized Loss on Marketable Securities Unrealized loss on marketable securities for the fiscal year ended December 28, 2024 was approximately $1.1 million, as compared to a loss of approximately $925,000 for the fiscal year ended December 30, 2023.
The change was primarily driven by the acquisition of ALT5 Subsidiary in May 2024, as well as higher average debt balances during the period. 29 Table of Contents Unrealized Loss on Marketable Securities Unrealized loss on marketable securities for the fiscal year ended December 28, 2024 was approximately $1.2 million.
Cash used in financing activities from discontinued operations for the fiscal year ended December 30, 2023 was approximately $2.2 million and was primarily due to the repayment of debt obligations in the amount of approximately $7.3 million, partially offset by proceeds from the issuance of debt obligations of approximately $5.1 million.
There was no cash used in investing activities for discontinued operations during the fiscal years ended December 27, 2025 or December 28, 2024 31 Table of Contents Cash provided by financing activities was approximately $716.8 million for the fiscal year ended December 27, 2025, and primarily relates to proceeds received from equity financing and the issuance of notes payable, partially offset by cash paid for fees related to the equity financing, cash paid for notes payable and related party notes payable.
The increase is due to the acquisition of ALT5 Subsidiary during May 2024, partially offset by no revenue from discontinued operations for the fiscal year ended December 28, 2024.
The increase is due to the acquisition of ALT5 Subsidiary during May 2024, as well as the acquisition of Mswipe during May 2025.
An unrealized gain or loss on marketable securities is recorded to mark to fair value securities received in connection to the sale of GeoTraq.
Unrealized gains or losses on marketable securities reflect the mark-to-fair-value adjustment for securities received in connection with the sale of GeoTraq. No such transactions occurred during the fiscal year ended December 27, 2025. Unrealized Loss on Cryptocurrency Assets Unrealized loss on cryptocurrency assets for the fiscal year ended December 27, 2025 was approximately $402.0 million.